Absci Corporation

What they do

Absci uses an AI-native drug creation platform, combining its generative design model Origin-1 with a lab-in-the-loop for rapid validation, to develop antibody therapeutics against underexplored biological targets. Its lead program, ABS-201, is an anti-prolactin receptor (PRLR) antibody with an extended half-life being developed for pattern hair loss and endometriosis. The company also advances preclinical programs such as ABS-202 for an undisclosed immunology and inflammation indication, and it maintains drug creation agreements with partners that generate revenue.

Revenue drivers

• Drug creation partnership agreements — Absci earns revenue from partnered drug creation programs, including project-based milestones and ongoing program activity. This is the company's primary revenue source, though total revenue is small, at $2.8 million for full-year 2025 and $0.5 million for the first half of 2026.
• Potential out-licensing of pipeline assets — The company states it may seek partnerships or out-licensing arrangements for select internal pipeline assets to provide non-dilutive capital, but no such revenue has been reported in the provided financials.
• ABS-201 (future product revenue) — ABS-201 is in Phase 1/2a clinical development and has no approved product or product revenue; any future revenue would depend on successful development and commercialization.

Recent performance

Total revenue for the second quarter of 2026 was $0.3 million, down from $0.6 million in the second quarter of 2025, due to the timing of project-based milestones and program mix under drug creation agreements. The net loss for the three months ended June 30, 2026 was $33.2 million, compared to $30.6 million in the prior-year period. For the six months ended June 30, 2026, revenue was $0.5 million and net loss was $62.8 million, versus revenue of $1.8 million and a net loss of $56.9 million in the first half of 2025. Research and development expenses increased by $5.1 million, or 14%, for the six-month period. As of June 30, 2026, the company reported an accumulated deficit of $687.6 million and cash equivalents and marketable securities of $201.1 million.

Strategy

Absci is focused on advancing ABS-201, its lead anti-PRLR antibody, through clinical development in two indications: pattern hair loss and endometriosis. The company plans to initiate a Phase 2 trial in endometriosis in the fourth quarter of 2026, subject to data from the ongoing HEADLINE trial and regulatory considerations. It continues to dose patients in the multiple ascending dose portion of the HEADLINE trial for pattern hair loss and expects interim proof-of-concept data in the second half of 2026, with full proof-of-concept data in early 2027. Absci is also advancing preclinical programs, including ABS-202, and may seek partnerships or out-licensing for select pipeline assets. In August 2026, the company completed a $100 million underwritten offering, including a $40 million strategic equity investment from Eli Lilly, which it says extends its cash runway into the second half of 2028.

Risks

• Need for additional capital — Absci has incurred significant losses since inception and will need to raise additional capital to fund operations and clinical development; if unable to do so on acceptable terms, it may not be able to continue developing its programs.
• Clinical and regulatory uncertainty — ABS-201 is in early clinical development and positive interim results are not necessarily predictive of later trial outcomes; the company has not yet completed any clinical trials, obtained marketing approvals, or commercialized a product.
• Dependence on third parties — Absci relies on third parties to conduct preclinical studies and clinical trials, and if those parties fail to perform as contractually required or miss deadlines, its programs could be delayed, more costly, or unsuccessful.
• Early-stage revenue and partnership risk — Revenue is small and variable, driven by the timing of milestones under drug creation agreements; if partners' programs fail to achieve milestones or partnerships are not maintained, revenue could decline further.

Outlook

Management expects interim proof-of-concept data from the HEADLINE trial in pattern hair loss in the second half of 2026 and full proof-of-concept data in early 2027. The company plans to initiate a Phase 2 clinical trial of ABS-201 in endometriosis in the fourth quarter of 2026, with potential proof-of-concept data in the second half of 2027. Absci states that its cash, cash equivalents, and marketable securities are sufficient to fund operations into the second half of 2028. It also continues to advance partnered programs and preclinical pipeline assets.